Copied to clipboard!

Gut microbiota biomarkers associated with Multiple Myeloma: The REMNANT Study

We aimed to investigate the association between gut microbiota composition and multiple myeloma–related clinical parameters, including treatment response, clinical outcomes, and treatment-related adverse effects

Type: Metagenomics
Archive: Federated EGA Norway Federated EGA Node

1 Dataset

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD50000003072	This dataset contains longitudinal shotgun metagenomic sequencing of stool samples collected across two time points from patients with newly diagnosed multiple myeloma (153 patients , 306 samples total). The suffix "scr" denotes the screening time point, when patients were enrolled in the study and samples were collected before initiation of treatment. Following inclusion, patients received standard multiple myeloma treatment according to Norwegian clinical guidelines. The treatment consisted of four cycles of induction therapy with bortezomib, lenalidomide, and dexamethasone (VRd), followed by autologous stem cell transplantation (ASCT) for eligible patients, and subsequently four cycles of consolidation therapy with VRd. The second stool sample was collected after completion of consolidation therapy. Therefore, samples with the suffix "post_con" represent the post-consolidation time point. This is the time point which MRD was measured. Samples were sequenced on the Illumina NovaSeq X platform. Raw data consists of paired FASTQ files per sample.	Illumina NovaSeq X	306